Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
| Autor: | F. Stephen Hodi, Kevin J. Harrington, Archie N. Tse, David C. Madoff, Jason J. Luke, Andrea Marie Perrone, Lawrence H. Schwartz, Anuradha D. Khilnani, Robert H.I. Andtbacka, Aurélien Marabelle, Gregory V. Goldmacher |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Metastatic melanoma medicine.medical_treatment MEDLINE 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Humans Medicine Response criteria Review Articles Response Evaluation Criteria in Solid Tumors Clinical Trials as Topic business.industry Neoplasms therapy Immunotherapy Neoplasms diagnosis 030220 oncology & carcinogenesis business 030215 immunology |
| Zdroj: | Journal of Clinical Oncology |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response Evaluation Criteria in Solid Tumors (RECIST) is not suitable for assessing responses separately for injected and noninjected tumors. Building on RECIST concepts, we propose an IT immunotherapy RECIST (itRECIST) to capture data and assess local and systemic responses in a standardized fashion for clinical trials involving IT immunotherapies. Methods: itRECIST will address the unique needs of IT immunotherapy trials but, where possible, aligns with RECIST 1.1 and iRECIST. It does not dictate which lesions to inject but provides guidelines for collecting data and assessing response as treatment evolves. Results: itRECIST enables overall response assessment, separate response assessments in injected and noninjected lesions, and continued assessment following modifications of therapy at initial progression. At baseline, lesions are classified into 4 categories: target injected, target noninjected, nontarget injected, and nontarget noninjected. After baseline, lesions can be reclassified from noninjected to injected if the investigator decides to change the lesions to inject, but target and nontarget designations never change. Overall response at each assessment is based on target lesion response (injected and noninjected), nontarget lesion response, and absence/appearance of new lesions. Noninjected lesion response is determined by comparing tumor burden with baseline and nadir values. Injected lesion assessment is based on visit-to-visit changes in the lesions injected during treatment and on a combined assessment once the patient is off treatment. A new response category is defined to capture progression that would be “confirmed” per iRECIST even though injected lesions are responding and therapy continues. Multiple examples have been created to aid in training and adoption. Conclusions: itRECIST is an important step toward a standardized method of response assessment for this promising and evolving therapeutic modality. The proposed guidelines can be adopted into trial protocols and routine clinical practice without the need for complex additional assessments by treating physicians. Until there is evidence to support wider use, itRECIST is intended only to support standardized collection of data and to facilitate exploratory analysis. Authors G.V.G. and A.D.K. contributed equally to this work. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|